Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70054 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Molecular Oncology, 2025. Verfasst von Charles Swanton und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Circulating Tumor DNA, Mutation, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech, Foundation Medicine.
Abstract (Originalsprache)
Immune checkpoint inhibitors are important for treatment across tumor types but are not universally effective in controlling disease. Early understanding of tumor response, or lack thereof, can inform treatment decisions. This study evaluates changes in circulating tumor DNA (ctDNA) and blood tumor mutational burden (bTMB) for associations with response to programmed cell death 1 ligand 1 (PD‐L1) blockade. We sequenced cell‐free DNA collected at the start of therapy, on treatment, and at the end of therapy for 153 patients treated with atezolizumab as part of the pan‐tumor MyPathway study (NCT02091141). ctDNA tumor fraction (TF) and bTMB were assessed for correlation with progression‐free survival (PFS) and overall survival (OS). We found that molecular response (MR, ≥50% decrease in TF at cycle 3 day 1) was associated with improved PFS (9.7 vs 1.5 months from C3D1; HR = 0.27) and OS (21.1 vs 14.3 months from C3D1; HR = 0.44). These findings were consistent when limited to patients with stable disease (SD; PFS HR = 0.55; OS HR = 0.39). bTMB was correlated with tissue‐based TMB (tTMB) when TF was high (≥1%), but not with OS in this cohort. In total, 61% of baseline samples had predicted clonal hematopoiesis (CH) variants. No correlation between maximum variant allele frequency (maxVAF) of predicted CH and TF was seen. In summary, MR is associated with outcomes for patients treated with atezolizumab and could stratify patients with SD. While CH was common, maxVAF for CH variants was not associated with ctDNA TF. Quantification of ctDNA enables therapy response monitoring and is critical for interpretation of bTMB as a proxy for tTMB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
- Department of Oncology, University College London Hospitals, London, UK.
- Foundation Medicine, Inc., Boston, MA, USA.
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- University of Adelaide, Adelaide, Australia.
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
ORCID-Profile: Charles Swanton, Russell W Madison, Christopher J Sweeney, Lincoln W Pasquina
Förderung
- Genentech
- Foundation Medicine
Zitieren
APA
Swanton, C., Madison, R. W., Tambaoan, C. F. B., Meric-Bernstam, F., Sweeney, C. J., Kurzrock, R., Burris, H. A., Spigel, D. R., Tukachinsky, H., Hughes, J., Malato, J., Yoo, B., Szado, T., Schwab, C., Pasquina, L. W., Gasco, A., Schulze, K., & Friedman, C. F. (2025). Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab. Molecular Oncology. https://doi.org/10.1002/1878-0261.70054
Vancouver
Swanton C, Madison RW, Tambaoan CFB, Meric-Bernstam F, Sweeney CJ, Kurzrock R, et al. Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab. Molecular Oncology. 2025. doi:10.1002/1878-0261.70054
BibTeX
@article{Swanton2025,
author = {Swanton, Charles and Madison, Russell W and Tambaoan, Candice Francheska B and Meric-Bernstam, Funda and Sweeney, Christopher J and Kurzrock, Razelle and Burris, Howard A and Spigel, David R and Tukachinsky, Hanna and Hughes, Jason and Malato, Julia and Yoo, Bongin and Szado, Tania and Schwab, Cheryl and Pasquina, Lincoln W and Gasco, Amaya and Schulze, Katja and Friedman, Claire F},
title = {Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70054}
}
EUVIMED